Literature DB >> 25681005

Obsessive-compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults.

Naomi A Fineberg1, Samar Reghunandanan2, Helen B Simpson3, Katharine A Phillips4, Margaret A Richter5, Keith Matthews6, Dan J Stein7, Jitender Sareen8, Angus Brown2, Debbie Sookman9.   

Abstract

This narrative review gathers together a range of international experts to critically appraise the existing trial-based evidence relating to the efficacy and tolerability of pharmacotherapy for obsessive compulsive disorder in adults. We discuss the diagnostic evaluation and clinical characteristics followed by treatment options suitable for the clinician working from primary through to specialist psychiatric care. Robust data supports the effectiveness of treatment with selective serotonin reuptake inhibitors (SSRIs) and clomipramine in the short-term and the longer-term treatment and for relapse prevention. Owing to better tolerability, SSRIs are acknowledged as the first-line pharmacological treatment of choice. For those patients for whom first line treatments have been ineffective, evidence supports the use of adjunctive antipsychotic medication, and some evidence supports the use of high-dose SSRIs. Novel compounds are also the subject of active investigation. Neurosurgical treatments, including ablative lesion neurosurgery and deep brain stimulation, are reserved for severely symptomatic individuals who have not experienced sustained response to both pharmacological and cognitive behavior therapies.
Copyright © 2015. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Compulsive; Obsessive; Pharmacotherapy

Mesh:

Substances:

Year:  2015        PMID: 25681005     DOI: 10.1016/j.psychres.2014.12.003

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  24 in total

1.  Refractory social anxiety disorder.

Authors:  Michael Van Ameringen; Beth Patterson
Journal:  J Psychiatry Neurosci       Date:  2017-01       Impact factor: 6.186

2.  Cognitive Inflexibility in OCD and Related Disorders.

Authors:  Samuel R Chamberlain; Jeremy E Solly; Roxanne W Hook; Matilde M Vaghi; Trevor W Robbins
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 3.  Obsessive-compulsive disorder.

Authors:  Dan J Stein; Daniel L C Costa; Christine Lochner; Euripedes C Miguel; Y C Janardhan Reddy; Roseli G Shavitt; Odile A van den Heuvel; H Blair Simpson
Journal:  Nat Rev Dis Primers       Date:  2019-08-01       Impact factor: 52.329

Review 4.  Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder.

Authors:  Reilly R Kayser
Journal:  J Clin Psychiatry       Date:  2020-09-08       Impact factor: 4.384

5.  Defining clinical severity in adults with obsessive-compulsive disorder.

Authors:  Eric A Storch; Alessandro S De Nadai; Maria Conceição do Rosário; Roseli G Shavitt; Albina R Torres; Ygor A Ferrão; Euripedes C Miguel; Adam B Lewin; Leonardo F Fontenelle
Journal:  Compr Psychiatry       Date:  2015-08-15       Impact factor: 3.735

Review 6.  Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway.

Authors:  Alexandre Vallée; Yves Lecarpentier; Jean-Noël Vallée
Journal:  Mol Psychiatry       Date:  2021-04-09       Impact factor: 15.992

Review 7.  Pharmacotherapeutic Strategies and New Targets in OCD.

Authors:  Christopher Pittenger
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 8.  Pharmacogenetics of Obsessive-Compulsive Disorder: An Evidence-Update.

Authors:  Gwyneth Zai
Journal:  Curr Top Behav Neurosci       Date:  2021

9.  Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Brian P Brennan; Lorrin Koran; Carol A Mathews; Gerald Nestadt; Michele Pato; Katharine A Phillips; Carolyn I Rodriguez; H Blair Simpson; Petros Skapinakis; Dan J Stein; Eric A Storch
Journal:  Psychiatry Res       Date:  2021-03-04       Impact factor: 11.225

10.  Calcium Signaling Pathway Is Associated with the Long-Term Clinical Response to Selective Serotonin Reuptake Inhibitors (SSRI) and SSRI with Antipsychotics in Patients with Obsessive-Compulsive Disorder.

Authors:  Hidehiro Umehara; Shusuke Numata; Atsushi Tajima; Akira Nishi; Masahito Nakataki; Issei Imoto; Satsuki Sumitani; Tetsuro Ohmori
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.